CD28 and autoimmune disease: Thus, when CD28 superagonistic antibodies (CD28SAb) were discovered to preferentially activate and expand immunosuppressive regulatory T (Treg) cells11, pre-clinical experiments have been performed to evaluate the potential use of these CD28SAbs to ameliorate the onset, progression, and clinical course of human autoimmune diseases.